Clinical trials: End-stage Kidney Disease
Kidney Disease, Chronic
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis
This observational, prospective, multicenter study will describe the mean dose of Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease.
- Trial name
- NCT01318512
- Where
- Czechia
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease
Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
More than 80% of patients with end stage renal disease have hypertension; 70% of whom are poorly controlled using conventional Hemodialysis therapy.
- Trial name
- NCT00759967
- Testing
- Microneurography, Bioimpedance testing
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Ottawa Hospital Research Institute
End Stage Renal Disease, Hemodialysis Access Failure
Acoustic Analysis of VA Sounds
End-stage renal disease (ESRD) is a growing global health problem, strictly connected with progressive ageing population and longer survival of patients living on renal replacement therapy.
- Trial name
- VAsound (NCT05612022)
- Testing
- AVF creation, AVG creation
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
End Stage Renal Disease, Arteriovenous Fistula
Trial of Fistula Versus Graft in Elderly Patients
This open-label pilot randomized controlled trial will test the feasibility and safety of randomizing patients over 65 years old who start hemodialysis with a tunneled dialysis catheter (TDC), and are eligible to receive either…
- Conditions
- End Stage Renal Disease, Arteriovenous Fistula, Arteriovenous Graft
- Trial name
- NCT03668002
- Testing
- Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Pittsburgh
Anemia, End Stage Renal Disease
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with end stage renal disease undergoing chronic hemodialysis.
- Trial name
- NCT02260193
- Testing
- AKB-6548
- Where
- 16 sites in United States
- Volunteers
- 94 people
- Sponsor
- Akebia Therapeutics
Chronic Renal Failure, Diabete Type 2
Symbiotics and Systemic Inflammation in Chronic Kidney Disease
Main objective: To assess the effectiveness of treatment with symbiotics on the chronic systemic inflammation observed in chronic renal failure 4 months after the start of treatment.
- Conditions
- Chronic Renal Failure, Diabete Type 2, Systemic Inflammation
- Trial name
- SISMIC (NCT04769687)
- Testing
- probiotic Vivomixx®, prebiotic Orafti®Synergy1
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hyperphosphatemia, Kidney Failure
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
- Trial name
- NCT01191255
- Where
- 56 sites in United States, Israel and 1 more
- Volunteers
- 441 people
- Sponsor
- Keryx Biopharmaceuticals
Renal Impairment
Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function
Evaluation of the pharmacokinetics (PK) of SPR206 in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.
- Trial name
- NCT04865393
- Testing
- SPR206
- Where
- 2 sites in New Zealand
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Kidney Failure, Chronic, Hemodialysis Complication
The Pristine Post-Market Study
This is a prospective, multi-center, single-arm study designed to assess the safety and performance of the Pristine™ Long-Term Hemodialysis Catheter.
- Conditions
- Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure
- Trial name
- NCT05228132
- Testing
- Pristine™ Long-Term Hemodialysis Catheter
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- C. R. Bard
Renal Impairment
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
- Trial name
- NCT06318676
- Testing
- Mezigdomide
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene
End Stage Renal Disease
A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT03795558
- Testing
- Etelcalcetide
- Where
- Austria
- Volunteers
- 37 people
- Sponsor
- Prim. Priv. Doz. Dr. Daniel Cejka
End Stage Renal Disease
An Effectiveness-Implementation Trial of SPIRIT in ESRD
Despite advances in dialysis, only 50% of dialysis patients are alive 3 years after the onset of end-stage renal disease (ESRD).
- Trial name
- NCT03138564
- Testing
- SPIRIT, Comparison Condition
- Where
- 39 sites in United States
- Volunteers
- 852 people
- Sponsor
- Emory University
Anemia, Chronic Kidney Diseases
Effect of rEPO in FGF23 in ESRD Patients
Objective: To evaluate the effects of recombinant Erythropoietin (rEPO) in plasma levels of Fibroblast Growth Factor 23 (FGF23) in End-Stage Renal Disease (ESRD) patients in hemodialysis.
- Trial name
- NCT03803514
- Testing
- Recombinant EPO
- Where
- Chile
- Volunteers
- 60 people
- Sponsor
- University of Chile
End-stage Kidney Disease, End-stage Renal Disease
The Optiflow Patency and Maturation Study
The objective of this study is to assess the performance and safety of the Optiflow Anastomotic Connector (Optiflow) when used to facilitate the creation of autogenous arteriovenous fistula (AVF) anastomoses.
- Trial name
- OPEN (NCT01921933)
- Testing
- Optiflow
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Bioconnect Systems, Inc
ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD)
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese…
- Conditions
- ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD), Hyperphosphatemia, Hyperphosphatemia in Chronic Kidney Disease
- Trial name
- RESPOND-1 (NCT07030595)
- Testing
- AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose
- Where
- 50 sites in China
- Volunteers
- 474 people
- Sponsor
- Alebund Pharmaceuticals
End Stage Renal Disease
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease
This pilot study of combined kidney and hematopoietic stem cell transplantation attempts to establish a protocol to induce immunological tolerance as a new strategy to prevent renal graft rejection.
- Trial name
- NCT02176434
- Testing
- Kidney and hematopoietic stem cell transplantation, hematopoietic stem cell
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University of Zurich
End-stage Renal Failure
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis (HD) patients.
- Trial name
- NCT01687699
- Testing
- Spironolactone
- Where
- Japan
- Volunteers
- 157 people
- Sponsor
- Dialysis Outcomes Heart Failure Aldactone Study Group
Chronic Renal Disease
Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient
The aim of this study is to investigate the role of immunosenescence in the HBV vaccination response in patients with renal insufficiency.
- Trial name
- IVVI (NCT02375711)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Staphylococcal Infections, Chronic Kidney Failure
Evaluation of Manufacturing Lot of StaphVAX
This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine.
- Trial name
- NCT00211900
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Nabi Biopharmaceuticals
End Stage Renal Failure on Dialysis
Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study
The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.
- Trial name
- NCT05927532
- Testing
- Argyle Safety Fistula Cannula with Anti-Reflux Valve
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mozarc Medical US LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.